IONS - Ionis Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

IONS is currently covered by 17 analysts with an average price target of $48.74. This is a potential upside of $15.18 (45.23%) from yesterday's end of day stock price of $33.56.

Ionis Pharmaceuticals's activity chart (see below) currently has 207 price targets and 205 ratings on display. The stock rating distribution of IONS is 77.78% BUY, 18.52% HOLD and 3.7% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 48.08% with an average time for these price targets to be met of 176.54 days.

Highest price target for IONS is $77, Lowest price target is $37, average price target is $61.

Most recent stock forecast was given by DEBJIT CHATTOPADHYAY from GUGGENHEIM on 01-May-2025. First documented stock forecast 12-Aug-2014.

Currently out of the existing stock ratings of IONS, 42 are a BUY (77.78%), 10 are a HOLD (18.52%), 2 are a SELL (3.7%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$64

$30.44 (90.70%)

16 days ago
(01-May-2025)

2/6 (33.33%)

$32.29 (101.83%)

11

Buy

$55

$21.44 (63.89%)

$60

17 days ago
(30-Apr-2025)

0/18 (0%)

$24.29 (79.09%)

Hold

$45

$11.44 (34.09%)

$47

1 months 23 days ago
(24-Mar-2025)

2/6 (33.33%)

$11.55 (34.53%)

79

Buy

$64

$30.44 (90.70%)

$60

2 months 27 days ago
(20-Feb-2025)

13/15 (86.67%)

$32.19 (101.19%)

345

Buy

$70

$36.44 (108.58%)

$70

2 months 27 days ago
(20-Feb-2025)

0/11 (0%)

$38.19 (120.06%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is IONS (Ionis Pharmaceuticals) average time for price targets to be met?

On average it took 176.54 days on average for the stock forecasts to be realized with a an average price target met ratio 48.08

Which analyst has the current highest performing score on IONS (Ionis Pharmaceuticals) with a proven track record?

ESTHER RAJAVELU

Which analyst has the most public recommendations on IONS (Ionis Pharmaceuticals)?

Esther Rajavelu has 8 price targets and 3 ratings on IONS

Which analyst is the currently most bullish on IONS (Ionis Pharmaceuticals)?

Yale Jen with highest potential upside - $64.44

Which analyst is the currently most reserved on IONS (Ionis Pharmaceuticals)?

Esther Rajavelu with lowest potential downside - -$0

Ionis Pharmaceuticals in the News

Ionis Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations

Ionis Pharmaceuticals (NASDAQ:IONS) First Quarter 2025 Results Key Financial Results Revenue: US$132.0m (up 11% from 1Q 2024). Net loss: US$147.0m (loss widened by 2.9% from 1Q 2024). US$0.93 loss per share. Our free stock report includes 1 warning sign investors should be aware of before investing in Ionis Pharmaceuticals. Read for free now.NasdaqGS:IONS Earnings and...

Ionis Pharmaceuticals Lifts Revenue Forecast After Strong Q1, Oppenheimer Says

Ionis Pharmaceuticals (IONS) reported strong Q1 financial results, driven by increased commercial an PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?